# US 2021/0340495 A1 · Method for inducing and differentiating pluripotent stem cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340495 A1
- Document ID: US20210340495A1
- Status: Published application
- Kind: A1
- Application number: 16/322,640
- Filed: 2017-07-27
- Published: 2021-11-04
- Earliest claimed: 2016-08-02
- Assignees: Universita' del Piemonte Orientale
- Applicants: Universita' del Piemonte Orientale
- Inventors: Antonia Follenzi; Cristina Olgasi; Maria Talmon
- Web page: https://patentgrep.com/patent/US20210340495A1

## CPC

- C12N 5/069: {Vascular Endothelial cells}
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 15/86: Viral vectors
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2502/1157: Monocytes, macrophages
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/76: Agarose, agar-agar
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention refers to a method for inducing pluripotent stem cells starting from somatic cells isolated from healthy and/or diseased individuals. The diseased individual is preferably affected by a genetic disease such as type A hemophilia, and the somatic cells from the diseased individual are genetically corrected for the mutation causing the disease preferably after being reprogrammed by the method of the present invention. A further aspect of the present invention refers to a method for differentiating induced pluripotent stem cells or embryonic stem cell-like into endothelial cells. Moreover, the present invention refers to the use of these cells as a medicament for treating a disease, in particular, a genetic disease such as type A hemophilia.

## Claims

### Claim 1

Method for inducing pluripotent stem cells or embryonic stem-like cells comprising the following steps:
(i) having differentiated and/or somatic cells said cells selected from: fibroblasts, lymphocytes, mononuclear cells, and CD34+ cells said cells being isolated from an individual;
(ii) reprogramming said cells by transducing the cells with a viral vector comprising a DNA sequence codifying at least one transcription factor selected from Oct4, Sox-2, Klf4 and c-Myc, and/or at least one small RNA molecule, preferably selected from: miRNA 302 and/or 367;
(iii) culturing said reprogrammed cells in a medium specific for stem cells to isolate stable reprogrammed cell clones characterized by not more than 4 copies of the viral vector.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mononuclear cells express at least one of the following markers: CD3, CD11b, CD14, and CD19; while the CD34+ cells are isolated from blood.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said individual is a healthy individual or a diseased individual, affected by a genetic disease comprising type A hemophilia.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the cells isolated from said diseased individual are genetically corrected by gene transfer or gene therapy.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the cells isolated from the type A hemophilia A affected individual are corrected, by gene therapy, by transducing into the diseased cells SEQ ID NO: 4, or any further gene involved in the coagulation cascade, wherein said transducing step comprises utilizing a viral vector comprising FVIII or its variant.

### Claim 6 (depends on 5)

The method according to claim 5, wherein FVIII or its variants, or said any further gene involved in the coagulation cascade is under the expression control of VEC promoter or its variants SEQ ID NO: 8, or FVIII promoter or its variants, SEQ ID NO: 9-18.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the cells are activated before step (ii) by culturing them at least 48-70 hours till 4-10 days in a serum-free and/or xeno-free medium comprising cytokines selected from: IL-3, IL-6, IL-7, stem cell factor (SCF), GM-CSF, thrombopoietin (TPO) and FLT3-ligand (FLT3L).

### Claim 8 (depends on 7)

The method according to claim 7, wherein the cytokines are used as a mixture.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the concentration of said cytokines ranges from 20 ng/ml to 100 ng/ml.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the concentration of the mixture of cytokines ranges between 5 and 25 ng/ml.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the viral vector is a lentiviral or retroviral vector.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the transducing step comprises is performed:
(i) inoculating the viral vector at least once at a multiplicity of infection (MOI) ranging from 5 to 100; and/or
(ii) on a cell amount ranging from 50.000 to 500.000; and/or
(iii) the viral vector has a titer ranging from 108 TU/ml to 1010 TU/ml; and/or
(iv) in a volume ranging from 50 μl to 500 μl.

### Claim 13 (depends on 1)

The method according to claim 1, wherein before step (iii) the cells are cultured for at least 48-72 hours in a serum free medium specific for stem cells comprising a pre-mixed cocktail of recombinant human cytokines comprising: IL3, IL7, IL6, GM-CSF and combination thereof; and/or SCF, FLT3-ligand, TPO, IL3.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the step (iii) is performed on a feeder layer or in feeder free condition.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the step (iii) lasts for fibroblasts at least 6 weeks, for CD34+ at least 6 weeks.

### Claim 16 (depends on 1)

Induced pluripotent stem cells or embryonic-like cells obtained/obtainable according to the method according to claim 1 characterized by:
Embryonic stem cell-like morphology compact with defined borders; and/or
Positive at alkaline phosphatase staining; and/or
Expressed stem cell nuclear and surface antigens, selected from the group consisting of: Oct4, Sox2, Klf4, Tra1-8 land Ssea-3/4; and/or
Unmethylated state of NANOG promoter; and/or
increase in telomeres therefore reactivation of telomerase complex; and/or
A normal karyotype; and/or
ability to differentiate all the cell types derived from the three germ layers.

### Claim 17

Method for differentiating induced pluripotent stem cells or any embryonic stem like cells into endothelial cells, wherein said method comprises the following steps
(i) inducing the formation of embryo bodies starting from the induced pluripotent stem cells or embryonic-like cells by:
(ia) plating the cells in a medium specific for embryo bodies at a concentration ranging from 5 to 50, colonies/plate to obtain embryo bodies formation;
(ib) after about 48 h from step (ia), culturing the obtained embryo bodies in suspension in the medium specific for embryo bodies further comprising BMP4 at a concentration ranging from 5 to 40 mg/ml;
(ic) after about 90-100 hours from step (ia) further adding to the medium FGF specific for embryo bodies at a concentration ranging from 5 to 40 ng/ml;
(id) after about 130-150 hours from step (ia) seeding the obtained embryo bodies on a gelatin coated plate in a medium specific for embryo bodies comprising: FGF at a concentration ranging from 5 to 40 ng/ml; and/or VEGF at a concentration ranging from 30 to 70 ng/ml;
(ie) after about 180-200 hours from step (ia) replacing the medium specific for embryo bodies with a medium including VEGF at a concentration 30-70 ng/ml until the end of culturing 20 days;
(ii) collecting the culture cells wherein said cultured cells are endothelial cells.

### Claim 18 (depends on 17)

Endothelial cells obtained by the method of claim 17.

### Claim 19 (depends on 16, 18)

A pharmaceutical composition comprising the induced pluripotent stem cells of claim 16 and/or the (differentiated) endothelial cells of claim 18 and at least one further pharmaceutical acceptable agents, such as carriers, diluents, adjuvants, growth factors.

### Claim 20 (depends on 16, 18, 19)

A method for treating a genetic disease with the induced pluripotent stem cells of claim 16, or the (differentiated) endothelial cells of claim 18, or the pharmaceutical composition of claim 19, wherein said genetic disease comprises type A hemophilia.
